Related Experiment Video
Updated: Jul 25, 2025
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying
Hélène Erasimus1, Vanessa Kolnik1, Frédéric Lacroix1
1Sanofi, Molecular Oncology, Vitry-sur-Seine, France.
Abstract:
The TGFβ signaling mediator SMAD4 is frequently mutated or deleted in colorectal and pancreatic cancers. SMAD4 acts as a tumor suppressor and its loss is associated with poorer patient outcomes. The purpose of this study was to find synthetic lethal interactions with SMAD4 deficiency to find novel therapeutic strategies for the treatment of patients with SMAD4-deficient colorectal or pancreatic cancers. Using pooled lentiviral single-guide RNA libraries, we conducted genome-wide loss-of-function screens in Cas9-expressing colorectal and pancreatic cancer cells harboring altered or wild-type SMAD4. The small GTPase protein RAB10 was identified and validated as a susceptibility gene in SMAD4-altered colorectal and pancreatic cancer cells. Rescue assays showed that RAB10 reintroduction reversed the antiproliferative effects of RAB10 knockout in SMAD4-negative cell lines. Further investigation is necessary to shed light on the mechanism by which RAB10 inhibition decreases cell proliferation of SMAD4-negative cells.
Significance:
This study identified and validated RAB10 as new synthetic lethal gene with SMAD4. This was achieved by conducting a whole-genome CRISPR screens in different colorectal and pancreatic cell lines. A future RAB10 inhibitors could correspond to a new therapeutic solution for patients with cancer with SMAD4 deletion.
Insights
Researchers identified RAB10 as a synthetic lethal gene interacting with SMAD4 deficiency in colorectal and pancreatic cancers. Targeting RAB10 may offer new therapeutic strategies for patients with SMAD4-altered tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- SMAD4 is a tumor suppressor frequently altered in colorectal and pancreatic cancers, with loss correlating to poor patient outcomes.
- Identifying synthetic lethal interactions with SMAD4 deficiency is crucial for developing targeted therapies.
Purpose of the Study:
- To discover novel synthetic lethal interactions with SMAD4 deficiency.
- To identify potential therapeutic targets for SMAD4-deficient colorectal and pancreatic cancers.
Main Methods:
- Genome-wide loss-of-function screens using pooled lentiviral single-guide RNA libraries.
- CRISPR screens in Cas9-expressing colorectal and pancreatic cancer cell lines with altered or wild-type SMAD4.
- Validation of candidate genes through rescue assays.
Main Results:
- The small GTPase RAB10 was identified as a susceptibility gene in SMAD4-altered cancer cells.
- RAB10 knockout exhibited antiproliferative effects in SMAD4-negative cell lines, which were reversed by RAB10 reintroduction.
- RAB10 was validated as a synthetic lethal gene partner to SMAD4.
Conclusions:
- RAB10 is a novel synthetic lethal gene partner to SMAD4 in cancer.
- Inhibitors targeting RAB10 represent a potential new therapeutic avenue for SMAD4-deficient colorectal and pancreatic cancers.
- Further mechanistic studies are needed to understand how RAB10 inhibition impacts cell proliferation.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...